Ocuphire Pharma logo

Ocuphire PharmaNASDAQ: OCUP

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

10 November 2005

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$23.14 M
-82%vs. 3y high
26%vs. sector
-vs. 3y high
-vs. sector
-89%vs. 3y high
31%vs. sector
-97%vs. 3y high
46%vs. sector

Price

regular market | Tue, 19 Nov 2024 14:30:00 GMT
$0.88-$0.03(-3.04%)

Dividend

No data over the past 3 years
$3.87 M$7.68 M
$3.87 M-$7.53 M

Analysts recommendations

Institutional Ownership

OCUP Latest News

The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics
prnewswire.com25 October 2024 Sentiment: POSITIVE

The resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD) RALEIGH, N.C. , Oct. 25, 2024 /PRNewswire/ -- The RD Fund (Retinal Degeneration Fund) – the venture arm of the Foundation Fighting Blindness – announces the all-stock acquisition of Opus Genetics, Inc. "Opus" (private) by Ocuphire Pharma, Inc., (Nasdaq: OCUP) a clinical-stage ophthalmic biopharmaceutical company.

Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology
globenewswire.com30 September 2024 Sentiment: POSITIVE

Published data from two Phase 3 clinical trials demonstrated rapid reversal of pharmacologically-induced mydriasis with favorable safety profile Published data from two Phase 3 clinical trials demonstrated rapid reversal of pharmacologically-induced mydriasis with favorable safety profile

Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July
globenewswire.com10 July 2024 Sentiment: POSITIVE

CEO to participate in ARVO SIG panel on oral medications for retinal diseases ZETA-1 Phase 2 clinical trial subset analysis to be presented during the ASRS 42 nd Annual Scientific Meeting FARMINGTON HILLS, Mich., July 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced it will participate in the Association for Research in Vision and Ophthalmology Special Interest Group (ARVO SIG) panel and the American Society of Retina Specialists (ASRS) 42 nd Annual Scientific Meeting, to highlight the potential of its lead oral candidate in development for diabetic retinopathy (DR).

Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June
globenewswire.com06 June 2024 Sentiment: POSITIVE

FARMINGTON HILLS, Mich., June 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that clinical updates on the Company's lead candidate APX3330 for diabetic retinopathy (DR) will be featured in upcoming presentations at the Clinical Trials at the Summit meeting on June 8 in Park City, Utah, and the Retinal Imaging Biomarkers & Endpoints Summit meeting June 25-27 in Boston.

Here's Why You Should Invest in Ocuphire Pharma (OCUP) Now
Zacks Investment Research11 January 2024 Sentiment: POSITIVE

Here, we discuss some reasons why buying Ocuphire Pharma (OCUP) stock now may turn out to be a prudent move.

Viatris and Ocuphire Pharma get FDA green light for eye treatment
Market Watch27 September 2023 Sentiment: POSITIVE

Viatris Inc. VTRS, and Ocuphire Pharma Inc. OCUP, +3.08% said Wednesday that the U.S. Food and Drug Administration has approved Ryzumvi to treat the side effects of pharmacologically-induced mydriasis, or dilation of pupils. About 100 million eye dilations are conducted in the U.S. each year to examine the retina and for other routine check-ups, the companies said in a release, but the dilation can last up to 24 hours and side effects include light sensitivity and blurred vision.

Ocuphire Pharma Plunges Following CEO Termination, New Appointment: The Bull, Bear Case - Ocuphire Pharma (NASDAQ:OCUP)
Benzinga21 April 2023 Sentiment: NEGATIVE

Ocuphire Pharma Inc OCUP was plunging over 22% at one point on Friday after the company announced it appointed Rick Rodgers to the role of interim CEO. An SEC filing, which stated former CEO Mina Sooch was terminated suggested there could be an issue at the company, which sparked fear.

Wall Street Analysts Believe Ocuphire Pharma, Inc. (OCUP) Could Rally 257.14%: Here's is How to Trade
Zacks Investment Research21 April 2023 Sentiment: POSITIVE

The consensus price target hints at a 257.1% upside potential for Ocuphire Pharma, Inc. (OCUP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Ocuphire Pharma, Inc. (OCUP) Is a Great Choice for 'Trend' Investors, Here's Why
Zacks Investment Research21 April 2023 Sentiment: POSITIVE

Ocuphire Pharma, Inc. (OCUP) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Ocuphire Pharma, Inc. (OCUP) is a Great Momentum Stock: Should You Buy?
Zacks Investment Research20 April 2023 Sentiment: POSITIVE

Does Ocuphire Pharma, Inc. (OCUP) have what it takes to be a top stock pick for momentum investors? Let's find out.

What type of business is Ocuphire Pharma?

Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.

What sector is Ocuphire Pharma in?

Ocuphire Pharma is in the Healthcare sector

What industry is Ocuphire Pharma in?

Ocuphire Pharma is in the Biotechnology industry

What country is Ocuphire Pharma from?

Ocuphire Pharma is headquartered in United States

When did Ocuphire Pharma go public?

Ocuphire Pharma initial public offering (IPO) was on 10 November 2005

What is Ocuphire Pharma website?

https://opusgtx.com

Is Ocuphire Pharma in the S&P 500?

No, Ocuphire Pharma is not included in the S&P 500 index

Is Ocuphire Pharma in the NASDAQ 100?

No, Ocuphire Pharma is not included in the NASDAQ 100 index

Is Ocuphire Pharma in the Dow Jones?

No, Ocuphire Pharma is not included in the Dow Jones index

When was Ocuphire Pharma the previous earnings report?

No data

When does Ocuphire Pharma earnings report?

Next earnings report date is not announced yet